These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22286828)

  • 1. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
    Salinas-Escudero G; Martínez-Valverde S; Reyes-López A; Garduño-Espinosa J; Muñoz-Hernández O; Granados-García V; Rely K
    Salud Publica Mex; 2012; 54(1):47-59. PubMed ID: 22286828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
    Neovius K; Buesch K; Sandström K; Neovius M
    Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
    Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
    J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
    Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
    J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab: a debate about funding.
    Fitzgerald DA; Isaacs D; Tobin B
    J Paediatr Child Health; 2012 May; 48(5):373-7. PubMed ID: 22296413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of cost-effectiveness of palivizumab for respiratory syncytial virus.
    Hussman JM; Li A; Paes B; Lanctôt KL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):553-67. PubMed ID: 23140255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.
    Blanken MO; Frederix GW; Nibbelke EE; Koffijberg H; Sanders EAM; Rovers MM; Bont L;
    Eur J Pediatr; 2018 Jan; 177(1):133-144. PubMed ID: 29168012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
    BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health economics and RSV.
    Carbonell-Estrany X; Lázaro y de Mercado P
    Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
    Nuijten MJ; Wittenberg W; Lebmeier M
    Pharmacoeconomics; 2007; 25(1):55-71. PubMed ID: 17192118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
    Lázaro y de Mercado P; Figueras Aloy J; Doménech Martínez E; Echániz Urcelay I; Closa Monasterolo R; Wood Wood MA; Fitch Warner K
    An Pediatr (Barc); 2006 Oct; 65(4):316-24. PubMed ID: 17020726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.